Stock comparison

ABBVvsVRTX

AbbVie IncvsVertex Pharmaceuticals Inc. Real data pulled from the alphactor.ai fundamentals pipeline — valuation, balance-sheet health, momentum, and analyst sentiment side by side.

ABBV

AbbVie Inc

$200.95

-12.05%

Biotechnology$362.8BNYSE

VRTX

Vertex Pharmaceuticals Inc

$436.59

-3.42%

Biotechnology$119.2BNASDAQ

60-day price, rebased to 100

ABBV -8.25% · VRTX -8.65%

Round-by-round

ABBV 3·VRTX 2· 1tie

EdgeVRTX

Valuation upside

-48.60% vs -43.30% to DCF fair value

EdgeVRTX

Balance-sheet strength

Altman Z 2.25 vs 12.39

EdgeABBV

Fundamental quality

Piotroski 7.00 vs 6.00 (of 9)

EdgeABBV

Growth + margins

Rule-of-40 37.70 vs 35.50

Tie

60-day momentum

-8.25% vs -8.65% price return

EdgeABBV

Market-cap liquidity

$362.8B vs $119.2B

Verdict

Across6categories,ABBVtakes the edge with3wins to2 (and 1 tie). Neither score is a buy signal on its own: run the full backtest and credibility tests on alphactor.ai before putting money on it.

Backtest a strategy onABBVorVRTX

Point-in-time backtests, 8-layer credibility pipeline, conviction scoring — free to start.